[go: up one dir, main page]

AR123156A1 - GLP-1R AGONISTS AND THEIR USES - Google Patents

GLP-1R AGONISTS AND THEIR USES

Info

Publication number
AR123156A1
AR123156A1 ARP210102186A ARP210102186A AR123156A1 AR 123156 A1 AR123156 A1 AR 123156A1 AR P210102186 A ARP210102186 A AR P210102186A AR P210102186 A ARP210102186 A AR P210102186A AR 123156 A1 AR123156 A1 AR 123156A1
Authority
AR
Argentina
Prior art keywords
glp
agonists
nonalcoholic
prediabetes
obesity
Prior art date
Application number
ARP210102186A
Other languages
Spanish (es)
Inventor
Wenge Zhong
Wei Guo
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of AR123156A1 publication Critical patent/AR123156A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proveen compuestos de fórmula (1), y composiciones farmacéuticas de los mismos, para usar, por ejemplo en el tratamiento de la diabetes mellitus tipo 2, prediabetes, obesidad, enfermedad de hígado graso no alcohólica, esteatohepatitis no alcohólica y enfermedad cardiovascular.Compounds of formula (1), and pharmaceutical compositions thereof, are provided for use, for example in the treatment of type 2 diabetes mellitus, prediabetes, obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cardiovascular disease.

ARP210102186A 2020-08-06 2021-08-05 GLP-1R AGONISTS AND THEIR USES AR123156A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2020107368 2020-08-06

Publications (1)

Publication Number Publication Date
AR123156A1 true AR123156A1 (en) 2022-11-02

Family

ID=77595623

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102186A AR123156A1 (en) 2020-08-06 2021-08-05 GLP-1R AGONISTS AND THEIR USES

Country Status (3)

Country Link
AR (1) AR123156A1 (en)
TW (1) TW202214622A (en)
WO (1) WO2022031994A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7558267B2 (en) 2019-10-25 2024-09-30 ギリアード サイエンシーズ， インコーポレイテッド GLP-1R modulating compounds
SI4097097T1 (en) 2020-01-29 2025-04-30 Gilead Sciences, Inc. Glp-1r modulating compounds
PE20231181A1 (en) 2020-08-06 2023-08-11 Gasherbrum Bio Inc HETEROCYCLIC GLP-1 AGONISTS
CN116406360A (en) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4317145A4 (en) 2021-03-24 2025-03-12 Shionogi & Co., Ltd PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 RECEPTOR AGONIST COMPRISING A FUSED RING
TWI843104B (en) 2021-05-20 2024-05-21 美商美國禮來大藥廠 Glucagon-like peptide 1 receptor agonists
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
EP4408840B1 (en) 2021-09-27 2025-08-13 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20240417393A1 (en) 2021-10-05 2024-12-19 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
CN118401519A (en) 2021-10-25 2024-07-26 拓臻制药公司 Compounds as GLP-1R agonists
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
CN119907794A (en) 2022-09-22 2025-04-29 盐野义制药株式会社 Condensed ring compound having GLP-1 receptor agonist effect
JP2025537254A (en) 2022-11-11 2025-11-14 イーライ リリー アンド カンパニー Glucagon-like peptide 1 receptor agonist
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CR20190289A (en) 2016-12-16 2019-08-21 Pfizer Glp-1 receptor agonists and uses thereof
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CN113227068B (en) * 2018-11-22 2023-06-13 上海齐鲁锐格医药研发有限公司 GLP-1R agonists and uses thereof
JP7558267B2 (en) * 2019-10-25 2024-09-30 ギリアード サイエンシーズ， インコーポレイテッド GLP-1R modulating compounds
SI4097097T1 (en) * 2020-01-29 2025-04-30 Gilead Sciences, Inc. Glp-1r modulating compounds

Also Published As

Publication number Publication date
WO2022031994A1 (en) 2022-02-10
TW202214622A (en) 2022-04-16

Similar Documents

Publication Publication Date Title
AR123156A1 (en) GLP-1R AGONISTS AND THEIR USES
CO2021008089A2 (en) Glp-1r agonists and their uses
DOP2021000208A (en) GLP-1R ANGONISTS AND USES THEREOF
CL2008002787A1 (en) Compounds derived from piperidine, which have modulating activity on the activity of the gpr 119 receptor; pharmaceutical composition comprising said compounds; and its use in the treatment of diseases such as type 1 and 2 diabetes, hyperpidemia, coronary heart disease, obesity and erectile dysfunction.
BRPI0817096B8 (en) thiazolidinedione analogue and pharmaceutical composition comprising it
UY32441A (en) PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND ITS USES
ECSP088120A (en) DERIVATIVES OF PIRIDAZINONA AS AGONISTS OF THE RECEPTOR OF THE HORMONE TIROIDEA
CL2011002185A1 (en) Compounds n, n-dimethyl-5- (2-methyl-6 - ((5-methylpyrazin-2-yl) -carbamoyl) benzofuran-4-yloxy) pyrimidin-2-carboxamide and salts thereof; pharmaceutical composition that includes them; and its use as activators of glucokinase to treat obesity and to treat or delay the progression or onset of type 2 diabetes and related disorders.
AR050540A1 (en) DERIVATIVES OF TRICICLIC ADAMANTILAMIDE AS INHIBITORS OF DEHYDROGENASE 11- BETA HYDROXYSTEROID
AR058901A1 (en) COMPOUNDS DERIVED FROM HIDANTOINE, USEFUL FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM
CL2008001839A1 (en) Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
CL2009001065A1 (en) Compounds derived from substituted 4-pyrimidinyl-1,3-thiazole (or 1,3-oxazole) sulfonamides, raf kinase inhibitors; pharmaceutical composition; preparation procedure; and use to treat a susceptible neoplasm, selected from barret's adenocarcinoma, carcinomas of the biliary tract and breast cancer, among others.
CL2012003009A1 (en) 3 - ((((3-Butyl-3-ethyl- (methyloxy) -1-1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,4benxothiazepin-8-yl) -methyl) -amino acid ) -pentanedioc; pharmaceutical composition that includes it; and its use in a metabolic disorder. pct.
GT200500307A (en) CHEMICAL COMPOUNDS
AR051405A1 (en) 2-CARBOXAMIDE (3-AMINO) THIOPHENE COMPOUNDS
PE20091425A1 (en) AMINOTIAZOLE DERIVATIVES
UY29827A1 (en) 2-AMINA-PYRIMIDINE-4- (2-METHYL-1- (TETRAHIDRO-2H-PIRAN-4-IL) -1-IMIDAZOL-5-Y1) SUBSTITUTED AND ITS DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR PREPARATION AND APPLICATIONS
CL2024002499A1 (en) Compounds as glp-1r agonists
CL2008002356A1 (en) Piperazine-amide sulfoxides; its preparation processes; the pharmaceutical compositions containing them; and its use in the treatment of diseases that are modulated with lxr alpha and / or beta agonists.
AR057222A1 (en) NEUROPEPRTIDO RECEPTOR AGONISTS -2
AR054786A1 (en) (6-FLUOR-BENZOL (1,3) DIOXOLIL) -MORFOLIN-4-IL-METANOMAS, CB1 RECEIVER MODULATORS
CL2009000599A1 (en) Compounds derived from substituted 4,5-dihydro-1h-pyrazol (4,3-g) benzothiazole; pharmaceutical composition; Useful for the treatment and prevention of cancer, infections, inflammatory and autoimmune diseases, among others.
MX2022006151A (en) 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS.
CL2008001261A1 (en) Compounds derived from 4- (benzoxanol-2-ylamino), npy y5 receptor ligands; pharmaceutical compositions containing them; and its use in the preparation of useful drugs in the treatment of depression, anxiety or obesity.
CR20230452A (en) Incretin analog-containing compositions and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure